reported that high numbers of CD163+ TAMs within the tumor infiltrating immune cell population of myeloma foci are associated with a dismal outcome in myeloma patients receiving bortezomib-based treatment regimens (66). The gene discussed is CD163; the disease is plasma cell myeloma.